Alliance Pharma Eyes OTC Acquisitions Following Strong 2021
UK-based Alliance Pharma saw sales rise double-digits in 2021, with acquisitions bolstering the performance of its established brands. Going into 2022, the company says it is in a strong position to pursue M&A in the consumer health space.
You may also be interested in...
Alliance Pharma has delivered on its commitment to expand its US operations with a deal for Perrigo's ScarAway and Kelo-cote brands. For Perrigo, the divestment brings its acquisition of HRA Pharma a step closer by satisfying competition concerns.
UK-based Alliance Pharma is in talks to expand its burgeoning US consumer health offering with a bolt on acquisition.
UK-based Alliance Pharma has strengthened its US offering by acquiring Biogix and its Amberen menopause supplement.